Novartis scores 19 points higher than Bayer on SINK's sustainability index.
Novartis is more sustainable according to SINK's open sustainability index, scoring 50/100 vs Bayer's 31/100 — a difference of 19 points.
Bayer scores 31/100 on the SINK sustainability index (Below expectations). Bayer reports comprehensive climate data with 21.9% Scope 1&2 reductions and SBTi-validated targets, but faces systematic controversies: 170,000+ Roundup lawsuits, $11B settlements, an OECD deforestation complaint, and glyphosate biodiversity damage. Emissions trajectory is inconsistent, Scope 3 gaps remain, and reliance on offsets undermines net-zero credibility.
Novartis scores 50/100 on the SINK sustainability index (Making progress). Novartis demonstrates solid operational decarbonization and supply-chain engagement but relies heavily on carbon credits for claimed neutrality. Nature strategy is nascent. A 2022 NGO assessment flagged 'very low integrity' targets—since partially addressed by SBTi validation—and the company retains trade association memberships with poor climate records.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard — 500+ companies ranked.
View full leaderboard →